Stockscreener 앱 받기
41.79
0.65%
0.27
Cg Oncology Inc 주식(CGON)의 최신 뉴스
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
CG Oncology Earnings Notes - Trefis
CG Oncology Appoints Christina Rossi to Board - MSN
CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating - TipRanks
SUO-CTC CG Oncology NMIBC Research Fellowship - Oncodaily
Will CG Oncology Inc. stock continue upward momentum2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC DataWhat's Changed - Sahm
Why CG Oncology Inc. stock is in analyst buy zoneMarket Rally & Real-Time Volume Trigger Notifications - DonanımHaber
Why analysts upgrade CG Oncology Inc. stock2025 Technical Overview & Precise Swing Trade Alerts - Улправда
Is CG Oncology Inc. stock supported by strong cash flows2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will CG Oncology Inc. stock beat EPS estimatesJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Aug Summary: Why analysts upgrade CG Oncology Inc. stockChart Signals & Weekly High Return Opportunities - Улправда
Is CG Oncology Inc. stock a safe investment in uncertain marketsGold Moves & Low Risk Growth Stock Ideas - Улправда
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce the Second Annual - GlobeNewswire
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology Inc Stock Analysis and ForecastHigh Yield Income Stocks & Technical + Fundamental = Smarter Investing - earlytimes.in
CG Oncology appoints Rossi to its Board of Directors - MSN
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
CG Oncology initiated with an Outperform at Wedbush - TipRanks
Wedbush initiates coverage on CG Oncology stock with Outperform rating By Investing.com - Investing.com Canada
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Insider Monkey
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - Sahm
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market - TipRanks
CG Oncology (NASDAQ:CGON) Sets New 1-Year HighStill a Buy? - MarketBeat
Cg Oncology Inc. (CGON) Live Share Price, Invest From India - INDmoney
CG Oncology, Inc. (CGON) stock price, news, quote and history - Yahoo Finance UK
CG Oncology Incannounced topline data from Bond-003 cohort P and first results from Core-008 cohort A - marketscreener.com
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
CG Oncology Reports Promising Efficacy and Safety Data for Cretostimogene in High-Risk Non-Muscle Invasive Bladder Cancer Trials - Quiver Quantitative
CG Oncology (NASDAQ: CGON) posts 83.7% CR, no Grade 3+ AEs in NMIBC trial data - Stock Titan
Schroder Investment Management Group Acquires 155,737 Shares of CG Oncology, Inc. $CGON - MarketBeat
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC - Urology Times
Will CG Oncology’s (CGON) Board Refresh and Cretostimogene Data Shape Its Bladder Cancer Strategy? - Sahm
Muscle Invasive Bladder Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, LLC, Protara Therapeutics, Binhui Biopharma - The Globe and Mail
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Midday Stock Roundup: Tilly’s, indie Semiconductor Up - Orange County Business Journal
CG Oncology (CGON) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CG Oncology Appoints Jim DeTore as Interim CFO - MSN
FY2025 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements - Sahm
Guidance Update: Will CG Oncology Inc. stock beat EPS estimates2025 Key Lessons & Proven Capital Preservation Tips - moha.gov.vn
Tejara Capital Ltd Purchases New Position in CG Oncology, Inc. $CGON - MarketBeat
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
Intech Investment Management LLC Acquires 6,503 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Shares Purchased by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Increases Stake in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Reaches New 12-Month HighHere's What Happened - MarketBeat
[Form 4] CG Oncology, Inc. Insider Trading Activity - Stock Titan
0.57%
자본화:
|
볼륨(24시간):